Physician
Baycare Aurora, LLC
Baycare Aurora, LLC was paid $25.37M by Medicaid between Jan 2018 and Dec 2024, across 383 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 11% of everything it billed.
33Billing provider infoBAYCARE AURORA, LLC
GREEN BAY, WI 54311
GREEN BAY, WI 54311
33aNPI1255387726assigned 05/26/2006
33bProvider typeSurgery Physician
28Total paid$25.37M
24GClaims1,116,838
24DCodes billed383
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Surgery Physician providers in Wisconsin
Rank by total paid#1 of 22
Median peer was paid$15K
This provider vs. median1,657×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 127,400 | $2.92M | |
| 2019 | 137,161 | $3.15M | |
| 2020 | 137,900 | $3.16M | |
| 2021 | 184,558 | $3.91M | |
| 2022 | 188,935 | $4.10M | |
| 2023 | 198,107 | $4.39M | |
| 2024incomplete | 142,777 | $3.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 11% | 54,342 | 47,212 | $2.88M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.2% | 12,151 | 7,970 | $1.57M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.8% | 22,967 | 20,442 | $1.46M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.2% | 40,522 | 14,797 | $1.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.5% | 20,563 | 17,868 | $1.15M |
| 80053 | Comprehensive metabolic panel | 3.1% | 38,682 | 28,705 | $777K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.5% | 10,677 | 9,197 | $632K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.2% | 25,172 | 9,732 | $549K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.1% | 3,029 | 2,837 | $538K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.0% | 16,479 | 15,086 | $508K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 4,792 | 2,971 | $437K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 5,844 | 5,327 | $422K |
371 more codes
| G0378 | Hospital observation service, per hour | 1.6% | 5,690 | $414K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 5,577 | $412K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 6,106 | $387K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.4% | 6,511 | $354K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 4,459 | $344K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.3% | 12,508 | $320K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.2% | 6,610 | $310K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 47,212 | $308K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 4,373 | $308K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 3,950 | $293K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 9,824 | $251K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,519 | $231K |
| 64483 | <1% | 1,190 | $224K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,571 | $216K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,163 | $215K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 2,276 | $213K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 9,121 | $210K |
| 64615 | <1% | 3,162 | $210K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,726 | $210K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,429 | $200K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,882 | $177K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,218 | $176K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,856 | $174K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,915 | $172K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,225 | $169K |
| 97161 | <1% | 3,996 | $155K | |
| 99201 | <1% | 2,752 | $147K | |
| 64493 | <1% | 661 | $142K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,073 | $142K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,702 | $141K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 787 | $130K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,879 | $129K |
| 82962 | <1% | 11,257 | $129K | |
| 97162 | <1% | 3,364 | $127K | |
| 83880 | <1% | 4,105 | $127K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,932 | $123K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,741 | $118K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,358 | $115K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 760 | $110K |
| 96415 | <1% | 1,066 | $109K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,713 | $106K |
| 84484 | <1% | 9,346 | $105K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,462 | $101K |
| 81025 | <1% | 9,095 | $101K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,225 | $95K |
| 27096 | <1% | 450 | $93K | |
| 64494 | <1% | 702 | $89K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 441 | $87K |
| 82077 | <1% | 2,674 | $78K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,216 | $76K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 14,069 | $74K |
| 83735 | <1% | 14,555 | $70K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,950 | $67K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 982 | $67K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,384 | $65K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,262 | $65K |
| 90961 | <1% | 1,305 | $65K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,801 | $65K |
| 93308 | <1% | 1,501 | $62K | |
| 81001 | <1% | 13,468 | $62K | |
| 83690 | <1% | 10,357 | $60K | |
| 87077 | <1% | 3,245 | $60K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,789 | $59K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 612 | $59K |
| 86850 | <1% | 2,172 | $59K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 120 | $58K |
| 93975 | <1% | 1,346 | $58K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,558 | $57K |
| 97165 | <1% | 1,679 | $56K | |
| 93971 | <1% | 1,615 | $55K | |
| 87081 | <1% | 2,128 | $55K | |
| 64635 | <1% | 229 | $53K | |
| 43249 | <1% | 355 | $52K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,712 | $51K |
| 84145 | <1% | 2,582 | $50K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 204 | $47K |
| 71250 | <1% | 1,524 | $46K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,465 | $46K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 793 | $45K |
| 83605 | <1% | 4,897 | $44K | |
| 76770 | <1% | 573 | $42K | |
| 96367 | <1% | 715 | $42K | |
| 62323 | <1% | 274 | $40K | |
| 72141 | <1% | 614 | $40K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 811 | $40K |
| 97166 | <1% | 1,005 | $40K | |
| 80047 | <1% | 1,033 | $38K | |
| 93321 | <1% | 851 | $37K | |
| 64636 | <1% | 269 | $37K | |
| 87070 | <1% | 2,323 | $36K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 708 | $35K |
| 86140 | <1% | 6,111 | $34K | |
| 93017 | <1% | 932 | $34K | |
| 97035 | <1% | 3,142 | $34K | |
| 74018 | <1% | 2,637 | $34K | |
| 85379 | <1% | 3,756 | $34K | |
| 76642 | <1% | 973 | $33K | |
| 85610 | <1% | 6,847 | $33K | |
| 81003 | <1% | 5,667 | $31K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,712 | $31K |
| 97116 | <1% | 2,426 | $31K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,837 | $30K |
| 84702 | <1% | 1,195 | $30K | |
| 93325 | <1% | 1,119 | $29K | |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | <1% | 506 | $28K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,126 | $28K |
| 97803 | <1% | 1,495 | $27K | |
| 82565 | <1% | 1,497 | $26K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 123 | $26K |
| 94010 | <1% | 1,507 | $25K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 921 | $25K |
| 82728 | <1% | 2,123 | $25K | |
| 12001 | <1% | 336 | $25K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 100 | $24K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 41 | $24K |
| 87040 | <1% | 1,872 | $23K | |
| 80061 | Lipid panel | <1% | 1,783 | $23K |
| 85027 | <1% | 3,989 | $23K | |
| 99480 | Subsequent intensive care, per day, low birth weight infant | <1% | 249 | $23K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,724 | $22K |
| 80143 | <1% | 1,778 | $22K | |
| 87210 | <1% | 1,961 | $21K | |
| 87186 | <1% | 2,454 | $21K | |
| 80179 | <1% | 1,743 | $21K | |
| 0240U | <1% | 624 | $20K | |
| 94729 | <1% | 1,364 | $20K | |
| 72100 | <1% | 1,554 | $20K | |
| 86900 | <1% | 2,282 | $18K | |
| 70498 | <1% | 218 | $18K | |
| 73221 | <1% | 291 | $18K | |
| 70496 | <1% | 186 | $16K | |
| 94726 | <1% | 1,322 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 599 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,043 | $15K |
| 93793 | <1% | 3,592 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,387 | $12K |
| 85730 | <1% | 2,470 | $12K | |
| 76536 | <1% | 261 | $11K | |
| 83550 | <1% | 1,691 | $11K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 203 | $11K |
| 82805 | <1% | 239 | $11K | |
| 84132 | <1% | 1,436 | $10K | |
| 87075 | <1% | 1,117 | $10K | |
| 94618 | <1% | 431 | $10K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 25 | $10K |
| 83615 | <1% | 2,619 | $10K | |
| 58661 | <1% | 13 | $10K | |
| 87205 | <1% | 2,480 | $10K | |
| 70486 | <1% | 268 | $10K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 73 | $10K |
| 97018 | <1% | 847 | $9K | |
| 83540 | <1% | 1,768 | $9K | |
| 95886 | <1% | 191 | $9K | |
| 87088 | <1% | 1,345 | $9K | |
| 90962 | <1% | 248 | $9K | |
| 73030 | <1% | 1,345 | $9K | |
| 73562 | <1% | 1,299 | $9K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,195 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 937 | $8K |
| 84100 | <1% | 2,408 | $8K | |
| 29848 | <1% | 12 | $8K | |
| 71271 | <1% | 227 | $8K | |
| 97163 | <1% | 242 | $8K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 206 | $8K |
| 82607 | <1% | 555 | $8K | |
| 72040 | <1% | 457 | $7K | |
| 76830 | Ultrasound, transvaginal | <1% | 320 | $7K |
| 64721 | <1% | 25 | $7K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 300 | $6K |
| 62321 | <1% | 29 | $6K | |
| 73502 | <1% | 751 | $6K | |
| 64484 | <1% | 54 | $6K | |
| 85652 | <1% | 2,625 | $6K | |
| 87807 | <1% | 284 | $6K | |
| 73630 | <1% | 1,813 | $6K | |
| 99223 | Prolong inpt eval add15 m | <1% | 151 | $6K |
| 93922 | <1% | 271 | $6K | |
| 93356 | <1% | 41 | $6K | |
| 86901 | <1% | 2,282 | $5K | |
| 90686 | <1% | 198 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $5K |
| 73130 | <1% | 929 | $5K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 75 | $4K |
| 12011 | <1% | 38 | $4K | |
| 93970 | <1% | 84 | $4K | |
| 82746 | <1% | 397 | $4K | |
| 73610 | <1% | 1,427 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,820 | $4K |
| 94060 | <1% | 216 | $4K | |
| 70491 | <1% | 53 | $4K | |
| 98940 | <1% | 321 | $4K | |
| 89051 | <1% | 377 | $4K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 117 | $4K |
| 77062 | <1% | 163 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 263 | $3K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 90 | $3K |
| 84703 | <1% | 341 | $3K | |
| 64490 | <1% | 15 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 241 | $3K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 53 | $3K |
| 85014 | <1% | 777 | $2K | |
| 87493 | <1% | 69 | $2K | |
| 93298 | <1% | 219 | $2K | |
| 82378 | <1% | 207 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 203 | $2K |
| 73110 | <1% | 816 | $2K | |
| 82803 | <1% | 109 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 269 | $2K |
| 98925 | <1% | 287 | $2K | |
| 88307 | <1% | 402 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,259 | $2K |
| 90715 | <1% | 140 | $2K | |
| 81002 | <1% | 276 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 25,712 | $2K |
| 99205 | Prolong outpt/office vis | <1% | 25 | $2K |
| 73564 | <1% | 317 | $2K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 33 | $2K |
| 97016 | <1% | 93 | $2K | |
| 92586 | <1% | 15 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 413 | $1K |
| 97802 | <1% | 83 | $1K | |
| 82550 | <1% | 240 | $1K | |
| 93295 | <1% | 54 | $1K | |
| 73700 | <1% | 40 | $1K | |
| 84439 | <1% | 181 | $1K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 72 | $1K |
| 82247 | <1% | 33 | $1K | |
| 96376 | <1% | 3,552 | $1K | |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 26 | $1K |
| 73140 | <1% | 381 | $983.65 | |
| 74019 | <1% | 198 | $912.67 | |
| 76937 | <1% | 123 | $892.01 | |
| 77080 | <1% | 16 | $848.04 | |
| 82271 | <1% | 100 | $844.57 | |
| 82330 | <1% | 48 | $817.15 | |
| 99245 | <1% | 13 | $802.41 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19,107 | $794.95 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 430 | $787.56 |
| 87015 | <1% | 169 | $781.77 | |
| 87045 | <1% | 65 | $753.79 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 16,961 | $744.50 |
| 87641 | <1% | 12 | $737.78 | |
| 93016 | <1% | 59 | $723.26 | |
| 82248 | <1% | 93 | $723.16 | |
| 77061 | <1% | 50 | $685.86 | |
| 77001 | <1% | 12 | $673.54 | |
| 80076 | <1% | 50 | $669.26 | |
| 36000 | <1% | 647 | $591.45 | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 37 | $588.50 |
| 82570 | <1% | 66 | $565.25 | |
| J2704 | Injection, propofol, 10 mg | <1% | 22,100 | $551.80 |
| 73080 | <1% | 214 | $519.59 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 30 | $500.42 |
| 0001A | <1% | 13 | $496.08 | |
| 20610 | <1% | 15 | $488.82 | |
| 77002 | <1% | 12 | $485.62 | |
| 88304 | <1% | 1,053 | $483.38 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,932 | $465.56 |
| 83970 | <1% | 13 | $435.04 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 321 | $430.02 |
| 87449 | <1% | 54 | $400.62 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,771 | $377.17 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 3,999 | $329.05 |
| 93018 | <1% | 33 | $309.76 | |
| 51798 | <1% | 68 | $305.85 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,612 | $302.68 |
| 87427 | <1% | 25 | $267.82 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,845 | $247.80 |
| 76870 | <1% | 12 | $238.85 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,736 | $230.54 |
| 93226 | <1% | 51 | $225.72 | |
| 93880 | <1% | 13 | $222.24 | |
| 90656 | <1% | 13 | $222.00 | |
| C1769 | Guide wire | <1% | 3,072 | $210.08 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,587 | $190.18 |
| 93294 | <1% | 37 | $189.59 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,475 | $180.04 |
| 93225 | <1% | 15 | $178.80 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 18,609 | $173.87 |
| 73590 | <1% | 33 | $157.20 | |
| 93244 | <1% | 13 | $154.04 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,702 | $143.44 |
| 87046 | <1% | 65 | $137.22 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 893 | $136.77 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,014 | $136.45 |
| 87147 | <1% | 27 | $130.56 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 142 | $119.91 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14,474 | $116.47 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 8,302 | $110.73 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 13 | $110.00 |
| 84156 | <1% | 30 | $95.22 | |
| 73560 | <1% | 29 | $92.71 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,545 | $82.24 |
| 85046 | <1% | 18 | $64.86 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 7,716 | $64.19 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 25,706 | $54.57 |
| J1815 | Injection, insulin, per 5 units | <1% | 2,606 | $54.27 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,249 | $53.54 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,357 | $50.88 |
| 99152 | <1% | 194 | $49.11 | |
| 85018 | <1% | 24 | $42.10 | |
| Q3014 | Telehealth originating site facility fee | <1% | 16 | $24.02 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,980 | $21.24 |
| G0250 | Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequently than once a week; billing units of service include 4 tests | <1% | 15 | $21.18 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,163 | $19.98 |
| 73090 | <1% | 24 | $18.61 | |
| 71101 | <1% | 20 | $18.61 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 304 | $13.30 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 2,263 | $11.35 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,728 | $11.19 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 184 | $10.41 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,552 | $9.07 |
| 88173 | <1% | 55 | $6.26 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,699 | $5.25 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,482 | $2.26 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | <1% | 299 | $0.75 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,747 | $0.71 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 814 | $0.24 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,071 | $0.22 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,368 | $0.14 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 708 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 733 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 365 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,711 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 688 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 145 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 225 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 362 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 1,533 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 2,716 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 519 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 32 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 149 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 162 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 52 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 17 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 27 | $0.00 |
| J8501 | Aprepitant, oral, 5 mg | 0% | 103 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 76 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 13 | $0.00 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 203 | $0.00 |
| J3590 | Unclassified biologics | 0% | 107 | $0.00 |
| A4364 | Adhesive, liquid or equal, any type, per oz | 0% | 13 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 332 | $0.00 |
| 88342 | 0% | 24 | $0.00 | |
| 80320 | 0% | 56 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 15 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 28 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 38 | $0.00 |
| 36416 | 0% | 32 | $0.00 | |
| A4212 | Non-coring needle or stylet with or without catheter | 0% | 1,366 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 2,144 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 239 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 2,120 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 1,836 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 94 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 326 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 236 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 303 | $0.00 |
| A4565 | Slings | 0% | 135 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 14 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 285 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 64 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 130 | $0.00 |
| 88302 | 0% | 12 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 55 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 188 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 23 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 17 | $0.00 |
| J3473 | Injection, hyaluronidase, recombinant, 1 usp unit | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, KARA (ASSISTANCE TREASURER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.